Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VS-6063 · 1 trial · 1 indication
Measured Via Adverse Events
ORR by RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| Defactinib (VS-6063) +Carboplatin/Paclitaxel | EXPERIMENTAL | Defactinib (VS-6063) +Carboplatin/Paclitaxel |
| Name | Type | Description |
|---|---|---|
| VS-6063 | DRUG | Phase 1: * First 3 patient cohort: VS-6063 200 mg PO twice daily * IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily, Phase 2: VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity. |
| Paclitaxel | DRUG | Phase 1: * First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle. * IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle. Phase 2: Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity. |
| Carboplatin | DRUG | Phase 1: * First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle. * IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle. Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity. |
Inclusion Criteria: * Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, diagnosed within 6 months of completing their most recent platinum-containing chemotherapy. * Patients with the following histologic cell types are eligible: Serous adenocarcinoma, endo...
Top 20 of 59 competitors
VS-6063 is an investigational small molecule being studied for the treatment of ovarian cancer. It is currently in Phase 1 clinical development, specifically being evaluated in patients with carboplatin-resistant ovarian cancer to assess its potential to re-sensitize tumors to carboplatin treatment.
VS-6063 targets FAK, which is focal adhesion kinase, a protein involved in cell signaling and tumor progression. By inhibiting FAK, the drug aims to interfere with cancer cell survival and growth, potentially making resistant ovarian cancer cells more responsive to chemotherapy.
VS-6063 is being developed by Verastem, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VSTM. The company is conducting clinical research to evaluate the drug's safety and efficacy in ovarian cancer.
VS-6063 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to determine its safety, dosing, and potential effectiveness in patients with ovarian cancer.
VS-6063 is being studied in the ROCKIF Trial (NCT03287271), a Phase 1 study titled 'Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK.' This trial is recruiting 90 participants in the United States and is open to adults aged 18 years and older.
VS-6063 is also known as defactinib, a selective inhibitor of focal adhesion kinase (FAK). In clinical trials, it is referred to by both names, and researchers use the compound to investigate its potential in overcoming resistance to carboplatin in ovarian cancer.